drugset / Trial / NCT05027867
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms from Part 1.
Timeline
- Start
- 2021-12-06
- Primary completion
- 2022-08-26
- Completion
- 2022-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navtemadlin | Small molecule | 180 mg | Oral |
| Subject | Navtemadlin | Small molecule | 240 mg | Oral |